Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide

Next Previous
X
Search
Trial Profile

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esketamine (Primary)
  • Indications Major depressive disorder; Suicidal ideation
  • Focus Registrational; Therapeutic Use
  • Acronyms Aspire I
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 20 Aug 2021 Results of a post hoc analyses of pooled data (NCT03039192, NCT03097133) changes from baseline at 24 hours after the first dose in Montgomery Asberg Depression Rating Scale total score and Clinical Global Impression-Severity of Suicidality Revised, in the full cohort and in subgroups published in the Journal of Clinical Psychopharmacology
    • 08 Feb 2021 According to a Janssen media release, the European Commission (EC) has authorized the expanded use of SPRAVATO (esketamine nasal spray) co-administered with oral antidepressant therapy in adults with a moderate to severe episode of MDD, as acute short term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency, based on results from two Phase 3 ASPIRE studies (ASPIRE I and II).
    • 11 Dec 2020 According to a Janssen media release, According to a Janssen media release, positive opinion is based on results from two Phase 3 ASPIRE studies (ASPIRE I and II).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top